Novartis and Kaiku Health to Jointly Create a Patient Monitoring...

Novartis and Kaiku Health to Jointly Create a Patient Monitoring and Management for Melanoma Patients

Healthcare Tech Outlook | Wednesday, April 28, 2021

With the joint production of a therapy-specific module for patients undergoing BRAF/MEK combination therapies for melanoma, Kaiku Health and Novartis hope to improve remote monitoring and support of these patients even more.

FREMONT, CA: In partnership with Novartis, a leading global medicines group, Kaiku Health, a pioneer of digital health intervention platforms in oncology, announced that it would create digital patient monitoring and management for melanoma patients.

"We are excited to collaborate with Novartis to develop together more personalized symptom management and patient support for melanoma patients. The introduction of several oral targeted therapies has resulted in growing need for improved ways for monitoring patients remotely during their treatments, and we are excited to work closely with Novartis and several leading cancer centers in further improving the digital patient monitoring and management of melanoma patients", says Lauri Sippola, the CEO, Kaiku Health.

Melanoma is a form of skin cancer that is less common than other forms, but it can spread to other areas of the body more easily. BRAF V600-positive melanoma affects about half of the patients, who may be candidates for BRAF and MEK inhibitor combination therapy. Patients usually take the combined medication outside of cancer centers because it is an oral targeted therapy. According to a study presented at the ESMO Virtual Congress in 20201, over 90 percent of centers that used telemedicine for patients receiving oral targeted therapies during the COVID-19 pandemic intend to do so again in the future.

With the joint production of a therapy-specific module for patients undergoing BRAF/MEK combination therapies for melanoma, Kaiku Health and Novartis hope to improve remote monitoring and support of these patients even more. The built module is intended to keep track of symptoms while also providing personalized symptom self-management advice and patient education. If a patient's symptoms worsen during treatment, the Kaiku Health platform will immediately alert the care team. Kaiku Health is available to patients as a mobile application for smartphones and tablets and a web browser-based application for computers.

The collaboration aims to build more sophisticated Machine Learning-based algorithms for personalizing the symptom management of patients undergoing BRAF and MEK combination therapies and generate novel insights on patient outcomes in a real-world environment.

Weekly Brief